Get the Stockscreener App
57.75
0.54%
0.31
Halozyme Therapeutics Inc stock is traded at $57.75, with a volume of 1.22M.
It is up +0.54% in the last 24 hours and up +3.24% over the past month.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
See More
Previous Close:
$57.44
Open:
$58
24h Volume:
1.22M
Relative Volume:
0.79
Market Cap:
$7.35B
Revenue:
$947.36M
Net Income/Loss:
$392.47M
P/E Ratio:
19.12
EPS:
3.02
Net Cash Flow:
$392.71M
1W Performance:
-0.93%
1M Performance:
+3.24%
6M Performance:
-7.11%
1Y Performance:
+50.55%
1-Day Range:
$57.32
$58.74
1-Week Range:
$56.07
$60.67
52-Week Range:
$37.73
$65.53
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Name
Halozyme Therapeutics Inc
Sector
Industry
Phone
(858) 794-8889
Address
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
57.75 | 7.35B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-19-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-07-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-29-24 | Initiated | TD Cowen | Outperform |
| Jul-24-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-24-23 | Initiated | H.C. Wainwright | Buy |
| May-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-27-23 | Resumed | Berenberg | Buy |
| Mar-16-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Dec-21-22 | Resumed | Morgan Stanley | Overweight |
| Nov-28-22 | Initiated | Wells Fargo | Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jun-14-21 | Initiated | Evercore ISI | Outperform |
| May-17-21 | Initiated | SVB Leerink | Outperform |
| May-11-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-21-21 | Reiterated | The Benchmark Company | Buy |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jul-01-20 | Initiated | The Benchmark Company | Buy |
| Feb-05-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-09-20 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Buy |
| Nov-05-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-19-18 | Resumed | Piper Jaffray | Neutral |
| May-11-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Oct-16-17 | Reiterated | Piper Jaffray | Overweight |
| Jan-06-17 | Downgrade | Citigroup | Buy → Neutral |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Nov-18-15 | Initiated | Citigroup | Buy |
| Sep-22-15 | Initiated | Barclays | Overweight |
| Jun-22-15 | Reiterated | JP Morgan | Overweight |
| Mar-03-15 | Reiterated | UBS | Buy |
| Feb-18-15 | Reiterated | MLV & Co | Buy |
| Jan-08-15 | Reiterated | MLV & Co | Buy |
View All
Halozyme Therapeutics Inc Stock (HALO) Latest News
Halozyme projects $1.15B-$1.225B revenue for 2025 with growth from key products - MSN
SEC Form 4 filed by PRESIDENT AND CEO Torley Helen - Quantisnow
Halozyme Therapeutics (HALO) Reports Q4 Earnings: What Key Metrics Have to Say - MSN
Benchmark Reaffirms "Buy" Rating for Halozyme Therapeutics (NASDAQ:HALO) - MarketBeat
Hussman Strategic Advisors Inc. Acquires 31,500 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
HALO's Q4 Earnings Beat, Higher Royalties Drive Revenue Growth - MSN
Meitav Investment House Ltd. Lowers Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts - Simply Wall St
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Handelsbanken Fonder AB - MarketBeat
Rhumbline Advisers Buys 5,833 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Assessing Halozyme Therapeutics: Insights From 9 Financial Analysts - Benzinga
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock - Yahoo Finance
HC Wainwright Forecasts Strong Price Appreciation for Halozyme Therapeutics (NASDAQ:HALO) Stock - MarketBeat
Halozyme Therapeutics Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Kestra Private Wealth Services LLC Sells 9,161 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Congress Asset Management Co. Cuts Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2024 Earnings Call Transcript - Insider Monkey
Kornitzer Capital Management Inc. KS Has $10.19 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock Holdings Boosted by Convergence Investment Partners LLC - MarketBeat
Halozyme stock target raised to $78 at JMP Securities - Investing.com India
Halozyme stock target raised to $78 at JMP Securities By Investing.com - Investing.com Nigeria
Halozyme Therapeutics Inc (HALO) Q4 2024 Earnings Call Highlights: Record Revenue and Strong ... By GuruFocus - Investing.com Canada
Halozyme Therapeutics: Q4 Earnings Snapshot - CT Insider
Halozyme Therapeutics Inc (HALO) Q4 2024 Earnings Call Highlights: Record Revenue and Strong ... - Yahoo Finance
Halozyme Therapeutics (HALO) Q4 Earnings and Revenues Top Estimates - MSN
Halozyme Therapeutics Inc (HALO) Q4 Earnings: EPS of $1.06 Beats - GuruFocus.com
Halozyme Therapeutics Q4 2024 Earnings Preview - MSN
Halozyme Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
Halozyme Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Halozyme shares surge 6% on strong Q4 results, upbeat 2025 outlook - Investing.com Nigeria
Earnings Flash (HALO) Halozyme Therapeutics Reports Q4 Adjusted EPS $1.26, vs. FactSet Est of $1.13 - Marketscreener.com
Halozyme Therapeutics Reiterates FY 2025 Guidance For EPS of $4.95-$5.35 on Revenue of $1.15-$1.225 Billion, vs FactSet Analyst Consensus of $4.90/Share on Revenue of $1.19 Billion - Marketscreener.com
Halozyme Therapeutics, Inc. Q4 Profit Increases, Beats Estimates - Nasdaq
HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS - PR Newswire
Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast? - MSN
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock - Yahoo Finance
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today - MSN
HALO Gears Up to Report Q4 Earnings: Here's What You Should Know - MSN
Davidson Capital Management Inc. Grows Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
State of Alaska Department of Revenue Has $2.22 Million Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Shaker Investments LLC OH Raises Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics (HALO) Projected to Post Earnings on Tuesday - MarketBeat
Halozyme rated overweight by Morgan Stanley, diversified revenue cited - MSN
Q1 EPS Estimate for Halozyme Therapeutics Lowered by Analyst - MarketBeat
Halozyme director Connie Matsui to exit board By Investing.com - Investing.com Canada
Halozyme director Connie Matsui to exit board - Investing.com
Halozyme Board Member Connie Matsui Steps Down - TipRanks
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by WCM Investment Management LLC - MarketBeat
Halozyme Therapeutics Inc Stock (HALO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Halozyme Therapeutics Inc Stock (HALO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| LaBarre Michael J. | SVP, CHIEF TECHNICAL OFFICER |
Feb 15 '25 |
Option Exercise |
0.00 |
3,386 |
0 |
177,142 |
| Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER |
Feb 16 '25 |
Option Exercise |
0.00 |
22,205 |
0 |
32,411 |
| LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER |
Feb 16 '25 |
Option Exercise |
0.00 |
27,831 |
0 |
33,402 |
| LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER |
Feb 15 '25 |
Option Exercise |
0.00 |
1,254 |
0 |
16,734 |
| Torley Helen | PRESIDENT AND CEO |
Feb 16 '25 |
Option Exercise |
0.00 |
109,694 |
0 |
744,548 |
| Torley Helen | PRESIDENT AND CEO |
Feb 15 '25 |
Option Exercise |
0.00 |
13,092 |
0 |
679,836 |
| Henderson Jeffrey William | Director |
Feb 03 '25 |
Sale |
56.30 |
5,000 |
281,517 |
38,611 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):